Table 2.
Comparison between PD-L1 high and low cases, and between PD-1 high and low casesa
| PD-L1 | PD-1 (on TILs) | |||||
|---|---|---|---|---|---|---|
| Low (N = 375) | High (N = 19) | Low (N= 316) | High (N = 76) | |||
| N (%) | N (%) | P-value | N (%) | N (%) | P-value | |
| Age (years, mean ± s.d.) | 55 ± 15 | 65 ± 15 | 0.002 | 55 ± 14 | 59 ± 16 | 0.031 |
| Sex | 0.029 | 0.650 | ||||
| M | 195 (52) | 5 (26) | 163 (52) | 37 (49) | ||
| F | 180 (48) | 14 (74) | 153 (48) | 39 (51) | ||
| Tumor differentiation | 0.008 | 0.098 | ||||
| Well | 10 (3) | 1 (5) | 9 (3) | 2 (3) | ||
| Moderate | 314 (85) | 11 (58) | 267 (85) | 57 (76) | ||
| Poor | 47 (13) | 7 (37) | 16 (21) | 37 (12) | ||
| Medullary features | < 0.001 | < 0.001 | ||||
| Yes | 10 (4) | 6 (46) | 5 (3) | 11 (21) | ||
| No | 223 (96) | 7 (54) | 118 (97) | 41 (79) | ||
| Signet ring cell features | 1.000 | 0.588 | ||||
| Yes | 5 (1) | 0 (0) | 0 (0) | 0 (0) | ||
| No | 353 (99) | 17 (100) | 296 (98) | 73 (100) | ||
| Mucinous features | 0.958 | 0.442 | ||||
| Yes | 65 (18) | 3 (18) | 57 (19) | 11 (15) | ||
| No | 293 (82) | 14 (82) | 244 (81) | 62 (85) | ||
| Location | 0.028 | < 0.001 | ||||
| Right colon | 142 (38) | 12 (63) | 106 (34) | 49 (64) | ||
| Left colon | 232 (62) | 7 (37) | 209 (66) | 27 (36) | ||
| Neoadjuvant treatment | 0.142 | 0.050 | ||||
| Yes | 39 (11) | 0 (0) | 36 (12) | 3 (4) | ||
| No | 324 (89) | 18 (100) | 270 (88) | 71 (96) | ||
| T-Stage | 0.323 | 0.238 | ||||
| Tis | 2 (1) | 0 (0) | 2 (1) | 0 (0) | ||
| T1 | 26 (7) | 2 (11) | 19 (6) | 9 (12) | ||
| T2 | 59 (16) | 5 (28) | 50 (16) | 14 (19) | ||
| T3 | 213 (58) | 6 (33) | 176 (57) | 43 (57) | ||
| T4 | 65 (18) | 5 (28) | 61 (20) | 9 (12) | ||
| N-stage | 0.067 | 0.001 | ||||
| N0 | 178 (51) | 9 (50) | 136 (45) | 51 (71) | ||
| N1 | 109 (31) | 9 (50) | 105 (35) | 13 (18) | ||
| N2 | 67 (19) | 0 (0) | 59 (20) | 8 (11) | ||
| AJCC stage | 0.397 | < 0.001 | ||||
| I | 56 (15) | 4 (21) | 41 (13) | 19 (25) | ||
| II | 110 (30) | 3 (16) | 82 (26) | 31 (41) | ||
| III | 123 (33) | 9 (47) | 113 (36) | 19 (25) | ||
| IV | 80 (22) | 3 (16) | 75 (24) | 7 (9) | ||
| Tumor-infiltrating lymphocyte score | < 0.001 | < 0.001 | ||||
| 0 – < 1 TIL per 10 high power fields | 71 (19) | 3 (16) | 69 (22) | 3 (4) | ||
| 1–1 to 15 TILs per 10 high power fields | 175 (47) | 0 (0) | 161 (51) | 13 (17) | ||
| 2 – > 15 but < 215 TILs per 10 high power fields | 101 (27) | 7 (37) | 76 (24) | 33 (43) | ||
| 3 – > 215 TILs per 10 high power fields | 26 (7) | 9 (47) | 8 (3) | 27 (36) | ||
| Peritumoral lymphocyte aggregates | 0.003 | < 0.001 | ||||
| 0 – None | 225 (61) | 4 (21) | 203 (65) | 24 (32) | ||
| 1 – Few | 145 (39) | 15 (79) | 109 (35) | 51 (68) | ||
| 2 – Many | 1 (0) | 0 (0) | 1 (0) | 0 (0) | ||
| Mismatch-repair protein status | < 0.001 | < 0.0001 | ||||
| Mismatch-repair proficient | 314 (85) | 7 (37) | 277 (89) | 41 (55) | ||
| Mismatch-repair deficient | 55 (15) | 12 (63) | 34 (11) | 34 (45) | ||
| PD-1 expression on TILs | < 0.001 | |||||
| Low | 309 (83) | 6 (32) | ||||
| High | 63 (17) | 13 (68) | ||||
Abbreviations: AJCC, American Joint Committee on Cancer; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; TILs, tumor-infiltrating lymphocytes.
a
Number of cases for each category may be less than the total due to lack of data on several cases. Statistically significant P-values (P < 0.05) are highlighted in bold.